



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ


1C866 U.S. 810
09/615736
07/13/00

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 6 July 2000

15 JUL 99 E462104-4 D01631
P01/7700 0.00 - 9916536.7

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Fee: £0

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

1. Your reference

40889/HRW

2. Patent application number

(The Patent Office will fill in this part)

9916536.7

14 JUL 1999

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)Scarista Limited
Kings Park House
Laurelhill Business Park
Stirling FK7 9JQPatents ADP number (*if you know it*)

7590789001

If the applicant is a corporate body, give the country/state of incorporation

Isle of Man

4. Title of the invention

Nutritional or Pharmaceutical Compositions

5. Full name, address and postcode in the United Kingdom to which all correspondence relating to this form and translation should be sent

Reddie & Grose
16 Theobalds Road
LONDON
WC1X 8PL

91001

Patents ADP number (*if you know it*)6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

Country

Priority application
(*If you know it*)Date of filing
(*day/month/year*)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(*day/month/year*)8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer 'Yes' if:*

- a) *any applicant named in part 3 is not an inventor, or*
- b) *there is an inventor who is not named as an applicant, or*
- c) *any named applicant is a corporate body.*

See note (d))

YES

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document.

Continuation sheets of this form

Description	13
Claim(s)	4
Abstract	
Drawing(s)	1

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

YES

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

14 July 1999

H R WAKERLEY
0171-242 0901

12. Name and daytime telephone number of person to contact in the United Kingdom

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

PHARMACEUTICAL AND NUTRITIONAL COMPOSITIONS

In the past ten years evidence has accumulated which indicates that elevated blood and tissue levels of homocysteine indicate an increased risk of all forms of cardiovascular disease (including coronary heart disease, venous and arterial thrombosis and peripheral vascular disease) (M den Heijer et al, Arterioscler Thromb Vasc Biol 18: 356-361, 1998: M den Heijer et al Thromb Haemostas 80: 874-877, 1998: LM Taylor et al, J Vasc Surgery 29: 8-21, 1999: NJ Wald et al, Arch Intern Med 158: 862-867, 1998: H Refsum et al, Ann Rev Med 49: 31-62, 1998), of cerebrovascular disease and stroke (J-H Yoo et al, Stroke 29: 2478-2483, 1998: CDA Stehouwer et al, Arterioscler Thromb Vasc Biol 18: 1895-1901) of diabetes, pre-diabetes (insulin resistance or syndrome X) and its various complications including vascular disease, kidney disease, nerve damage and eye damage (S Neugebauer et al, Lancet 352: 454, 1998: AK Aarsand et al, J Internal Med 244: 169-174, 1998: EJ Giltay et al, Atherosclerosis 139: 197-198, 1998: E Okada et al, Diabetes Care 22: 484-490, 1999), of a range of psychiatric disorders including depression and schizophrenia (E Susser et al, Biol Psychiatry 44: 141-143, 1998: T Arinami et al, Am J Med Genetics 74: 526-528, 1997: C Gomes-Trolin et al, J Neural Trans, 105: 1293-1305, 1998: B Regland et al, J Neural Transm 98: 143-152, 1994: JE Albert et al, Nutrition Rev 55: 145-149, 1997: T Bottiglieri, Nutrition Rev 54: 382-390, 1996), of neurological disorders including Alzheimer's disease and other dementias (E Jensen et al, Arch Gerontol Geriatr 26: 215-226, 1998: R Clarke et al,

Arch Neurol 55: 1449-1455, 1998: M Lehmann et al, Dementia 10: 12-20, 1999), multiple sclerosis (STFM Frequin et al, J Neurol 240: 305-308, 1993: GA Qureshi et al, Biogenic Amines 12: 353-376, 1996) and 5 Parkinson's disease, of kidney disorders and kidney failure (T Tamura et al, Am J Kidney Dis 32: 475-481, 1998: A Vychytal et al, Kidney Int 53: 1775-1782, 1998) of inflammatory disorders, including inflammatory bowel 10 diseases and arthritis (SL Morgan et al, J Rheumatol 25: 441-446, 1998: M Cattaneo et al, Netherl J Med 52: S1-61, 1998), of ear and eye disorders including age-related macular degeneration, age-related hearing loss and tinnitus (DK Houston et al, Am J Clin Nutr 69: 564-71, 1999), of cancers (DG Weir et al, Am J Clin Nutr 15 68: 763-4, 1998: E Giovannucci et al, Ann Intern Med 129: 517-524, 1998) and of all-cause mortality (EK Hoogeveen et al, Netherlands J Med 52: S1-61, 1998). Homocysteine levels may also be elevated during obesity and particularly during its treatment (BF Henning et 20 al, Res Exp Med 198: 37-42, 1998). Homocysteine-lowering nutrients may also be of value in the treatment of pain (J Leuschner, Arzneim-Forsch 42: 114-115, 1992) and during pregnancy for the prevention of congenital disorders such as spina bifida and of 25 pregnancy problems such as pre-eclampsia or fetal growth restriction (M Leeda et al, Am J Obstet Gynecol 179: 135-139, 1998). The mechanism of these widespread associations between elevated homocysteine and disease remains unknown but is likely to be something which 30 operates at a fundamental biochemical level in many different tissues. One strong candidate is excessive oxidation promoted by homocysteine and its metabolites leading to changes in the functions of proteins and lipids (PB Young et al, Atherosclerosis 129: 67-71,

1997). The endothelium may be particularly vulnerable and since the endothelium is important in every tissue of the body this could provide a basis for the extraordinary range of pathology which is associated 5 with elevated homocysteine (JC Chambers et al. Circulation 99: 1156-1160, 1999).

The main determinants of elevated homocysteine levels are deficits of folic acid and of vitamin B12 and, to 10 a lesser extent, of pyridoxine and related substances with vitamin B6 activity. Homocysteine is mainly metabolised by conversion to methionine, which can then be used to make S-adenosyl-methionine which is used as 15 a methyl donor in many different essential reactions, including the regulation of DNA and RNA functions and the syntheses of phospholipids, neurotransmitters and complex carbohydrates. The conversion of homocysteine to methionine is catalysed by the enzyme methionine synthetase: methyl-cobalamin, one of the forms of 20 vitamin B12, plays a critical role in this reaction. A required co-factor for the enzyme is folic acid in the form of methyl-tetrahydrofolate. In the course of the reaction, a methyl group is transferred from 5-methyltetrahydrofolate to homocysteine, so producing 25 tetrahydrofolate and methionine. Adequate intake and absorption of both folic acid and vitamin B12 are therefore required to keep homocysteine levels low and to ensure proper methylation reactions.

30 A secondary route for the metabolism of homocysteine involves its conversion to cystathionine and then to cysteine in two separate reactions, both of which require vitamin B6 as a co-factor. Inadequate availability of pyridoxine or related molecules may

therefore make a contribution to elevated homocysteine levels.

Optimal control of homocysteine metabolism therefore requires optimal body levels of vitamins B12 and B6 and also of folic acid or methyltetrahydrofolate or any other related substance which can provide folate. Vitamin B6 must be provided at a dose of at least 2mg per day, and preferably 5mg to 200mg per day. Vitamin B12 is normally provided by injection but can be given by mouth, even in those who lack the gastric intrinsic factor required for efficient absorption from the gut. Daily oral doses of vitamin B12 of at least 200 μ g, and preferably 500 to 10,000 μ g are required to ensure adequate tissue levels in those such as the elderly in whom B12 absorption may not be fully normal. The vitamin B12 may be provided as cyanocobalamin or hydroxocobalamin or any other biologically active form of the vitamin. Hydroxocobalamin is the preferred form since it is relatively stable and does not act as a cyanide donor. Folic acid should be provided in a dose of at least 200 μ g/day and preferably more than 500 μ g/day. The best results in control of elevated homocysteine will be obtained by the appropriate oral administration of all three vitamins. Appropriate daily doses applicable to most people would be 1mg to 5mg of B12, preferably as hydroxocobalamin, 0.5 to 5mg of folic acid, and 2mg to 20mg of pyridoxine.

Essential fatty acids are another class of essential nutrients, so-called because they cannot be made within the body but have to be provided in the diet. There are two types of EFAs, n-3 (or omega-3) and n-6 (or omega-6) which are not interchangeable. The main

parent EFA of the n-6 group is linoleic acid, while the main parent fatty acid of the n-3 group is alpha-linolenic acid (figure 1). Although linoleic and alpha-linolenic acids are the most important EFAs in the diet, it is their metabolites which play the most important roles in the body. Although the metabolites cannot be synthesised de novo, they can be made from the parent EFAs by the pathways shown in figure 1. Particularly important members of the EFA families in terms of biological effects are dihomogammalinolenic acid (DGLA), arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

Just as elevated levels of homocysteine have been associated with a remarkably wide range of illnesses, so low levels of essential fatty acids, and particularly low levels of the metabolites DGLA, AA, EPA and DHA, have also been associated with a wide and very similar range of illnesses. The illnesses in which reduced levels of these fatty acids have been found include cardiovascular diseases, cerebrovascular diseases, thrombotic diseases, psychiatric diseases such as schizophrenia, depression and bipolar disorder, inflammatory diseases such as various forms of arthritis, eczema, asthma and inflammatory bowel disease, diabetes and its complications, kidney disease, neurodegenerative diseases like Alzheimer's disease and other dementias and Parkinson's disease, kidney diseases, many forms of cancer, and disorders of the reproductive system including male and female infertility and disorders of the breast and prostate (DF Horrobin, ed, Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine, Wiley-Liss, New York, 1990: DF Horrobin and CN Bennett,

Prostaglandins Leukotri Essential Fatty Acids, 60: in press, 1999: A Leaf et al, World Rev Nutr Diet 83: 24-37, 1998: DF Horrobin, Prostaglandins Leukotri Essential Fatty Acids, 53: 385-396, 1995).

5

Many studies have been performed in which EFAs have been used in attempts to treat diseases, including cardiovascular and cerebrovascular disorders, psychiatric and neurological disorders, renal disorders, inflammatory disorders of the skin, joints, respiratory and gastrointestinal systems, cancers and many other conditions. The EFAs which have been used have been particularly gamma-linolenic acid (GLA), DGLA, AA, EPA, and DHA, but also alpha-linolenic acid, linoleic acid and stearidonic acid. On the whole the results have shown beneficial effects but, equally, the effects have often been less than those hoped for by the authors.

20 Studies have also reported the levels of EFAs and the levels of homocysteine in patients or subjects: for example, in patients with end-stage renal disease, there has been reported an inverse relationship between the levels of homocysteine and the levels of DGLA, AA, EPA and DHA. Lowering homocysteine by treatment with folic acid produced elevations of these four fatty acids which were significant in the cases of DGLA and AA, but not significant in the cases of EPA and DHA (S Hirose et al. Jap J Nephrol 1998; 40: 8-16).
25 Similarly, in rats made folic acid deficient, homocysteine levels became elevated and at the same time plasma levels of AA, EPA and DHA fell, the last two significantly so (P Durand et al, Atherosclerosis 1996; 121: 231-243). In another study, human maternal

plasma homocysteine levels were related to fatty acid levels in the red cells of the babies. There was a strong inverse relationship between maternal homocysteine and baby DHA (H Bohles et al. Eur J 5 Pediatrics 158: 243-246, 1999).

The present invention is based on the inventors' observation that there may be a close relationship between the elevation of homocysteine and the deficits 10 of EFAs, especially of AA, EPA and DHA. EFAs, with their multiple double carbon-carbon bands, are highly susceptible to oxidation. Homocysteine and its metabolites could be promoting EFA-oxidation to reduce EFA levels.

15 Administration of the EFAs used in attempts to treat diseases may be being countered by their ongoing oxidation as a result of elevated levels of homocysteine. Thus the changes in EFA levels and the 20 therapeutic effects of the EFAs will be less than expected. Moreover, since some of the oxidised EFA metabolites can be toxic, the desirable effects may be counteracted by undesirable ones.

25 Equally, attempts to lower homocysteine by means of folic acid, vitamin B12 or vitamin B6, either alone or in combination have often had desirable effects, but sometimes those desirable effects have been less than expected. This can be explained if some of the 30 toxicity of homocysteine is attributable to loss of EFAs. Correction of elevated homocysteine will prevent the ongoing damage to the EFAs. However, since the EFAs cannot be synthesised de novo by the body, controlling homocysteine will do nothing to increase

the supply of EFAs to help replace those which have been lost.

5 The following invention thus provides the combined application of one or more EFAs, together with one or more homocysteine lowering agents, for use in therapy of any disorder, but particularly of those disorders discussed earlier in this specification. The 10 formulations of the present invention are set out in the attached claims.

15 The lowering of homocysteine will prevent ongoing damage to the EFAs, and so make the desirable results of EFA administration more likely. Equally, the provision of EFAs will help to replenish fatty acids lost through elevated homocysteine levels, and so make a desirable response to lowering homocysteine more likely.

20 EFAs and homocysteine lowering nutrients have been naturally coadministered in the form of human and artificial milks, eggs and of other nutrient complete foods. However, they have not previously been administered in pharmaceutical or nutritional 25 supplement dose forms, nor in the doses likely to be required for therapeutic as opposed to nutritional effects. In particular, oral administration of vitamin B12 in relatively high doses has rarely been employed, neither natural or artificial milks, nor multinutrient 30 mixes for oral or enteral administration, contain levels of vitamin B12 which are anywhere close to 200 µg/day. Similarly, these foods contain levels of folic acid and of vitamin B6 which are far below 100 µg/day for folic acid and 1.5mg per day vitamin B6.

For example, dried milk which is the complete food
richest in these nutrients contains only 0.23mg vitamin
B6, 2.0 µg vitamin B12 and 40 µg folic acid per 100g
[The Composition of Foods, AA Paul and DAT Southgate,
5 HMSO, London 1988]. 100g of dried milk products
provides about 500 calories and so it would be
impossible to consume more than about 500g/day of dried
milk. Even this large amount would only provide 1.15mg
vitamin B6 and 10.0 µg vitamin B12.

10

The EFAs in the compositions and uses of the present
invention may be in any form which leads to a rise in
the level of the relevant EFA molecule in the plasma or
in cell membranes. Appropriate forms include mono-,
15 di- and triglycerides, phospholipids, esters of any
form, including ethyl, propanediol or any other
appropriate form of ester, amides, salts, including
lithium, sodium and potassium salts, and any other
compounds which, following oral, parenteral or topical
20 administration lead to an increase in blood or tissue
levels of the EFAs concerned. Particularly appropriate
forms which are known to be highly compatible with
administration to the human or animal body are
triglycerides and ethyl esters, for example of GLA,
25 DGLA, AA, EPA or DHA. The EFAs may be administered in
doses of from 10mg to 100g per day, preferably 50mg to
20g per day, and very preferably 100mg to 5g/day. The
EFAs may be provided in the form of natural oils,
30 partially or completely purified natural oils in which
the other components have been removed, or chemically
derivatised pure or partially purified lipid forms.
The EFA component of the formulation must contain at
least 5% of the relevant EFA or EFA derivative,

preferably more than 15%, and very preferably more than 30%, 50%, 90% or 95%.

The homocysteine-lowering agents used in the compositions and uses of the present invention are selected from vitamin B12, folic acid or a related compound with similar biological activity and vitamin B6. The preferred form of vitamin B12 is hydroxocobalamin, though cyanocobalamin or any other biologically active form of the vitamin may be used. If present, more than 10 μ g/day vitamin B12 is required. The preferred dosage is at least 200 μ g, preferably 500 - 10,000 μ g, still preferably 1mg - 5mg per day. Folic acid may be used as it is or in the form of methyltetrahydrofolate or any other related substance which can provide folate. The preferred dosage is at least 200 μ g, preferably more than 500 μ g and still preferably 0.5 - 5 mg per day. Vitamin B6 may be used in the form of pyridoxine. If present, at least 1.5 mg/day vitamin B6 is required. The preferred dose is at least 2 mg, preferably 5 - 200 mg, still preferably 2 - 20 mg per day. Overall, it is preferred that at least 200 μ g/day homocysteine lowering agent is required, whatever the identity of the said agent(s).

The EFAs and homocysteine-lowering nutrients may be mixed together in powders or liquids, may be administered together in tablets, hard or soft gelatin capsules, microcapsules or any other appropriate dosage form known to those skilled in the art. The EFAs and the homocysteine-lowering nutrients may also be given in separate dosage forms but provided together in a single pack with instructions for daily administration of both components. The formulations may comprise

conventional diluent and/or excipients and flavouring agents may be added.

One of the problems of using EFAs either in nutrition 5 or in therapy is that they are easily oxidised within the body to a wide range of products, some of which may be harmful. The body has a system of antioxidant devices to deal with this, but not every individual may have adequate antioxidant defences. This is because 10 several of the key antioxidants are essential nutrients which must be provided in the diet and not all diets are adequate. It is therefore advantageous to provide with the formulations one or more antioxidants. Antioxidants of particular value are vitamin E in any 15 of its natural or artificial forms, coenzyme Q in any of its natural or artificial forms, alpha-lipoic acid in any of its natural or artificial forms and vitamin C in any of its natural or artificial forms. When the antioxidant component is required, it may include any 20 one or any combination of these agents. If present, the dosage of antioxidant is preferably from 1 mg to 5000 mg per day.

EXAMPLES

25

1. Hard or soft gelatin capsules containing 500mg of ethyl-eicosapentaenoate or of eicosapentaenoic acid triglyceride, together with 1mg of hydroxocobalamin, 1mg of folic acid and 2mg of pyridoxine, to be taken 30 two to four times a day.

2. A formulation as in 1 but in which the eicosapentaenoate is first microencapsulated with any

appropriate microencapsulating agent and then tabletted with the other ingredients.

5 3. A solution for oral administration in which 500mg of an eicosapentaenoate derivative, 1mg of folic acid, 1mg of hydroxocobalamin and 5mg of pyridoxine are present in 5ml with appropriate flavouring.

10 4. An emulsion for parenteral administration in which 500mg of the eicosapentaenoate derivative is emulsified in a total volume of 10ml, which includes in solution 1mg of hydroxocobalamin, 1mg of folic acid and 5mg of pyridoxine.

15 5-8. As examples 1 to 4 but in which the EFA is selected from arachidonic acid, gamma-linolenic acid, dihomogammalinolenic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid, linoleic acid or alpha-linolenic acid or their derivatives.

20 9-12. As examples 1 to 4, but in which two or three EFAs selected from the list in 1-8 are coadministered to give a total of 500mg of EFA per oral encapsulated or tabletted dosage form, per 5ml solution, or per 10ml parenteral emulsion.

25 13-24. As 1-12 but in which the only homocysteine-lowering component provided is vitamin B12.

30 25-36. As 1-12 but in which the only homocysteine-lowering component provided is folic acid.

37-48. As 1-12 but in which the only homocysteine-lowering component provided is vitamin B6.

49-96. As 1-48 in which one or more antioxidants selected from vitamin E, coenzyme Q, alpha-lipoic acid and vitamin C is added to the formulation. Vitamin E, coenzyme Q, alpha-lipoic acid and vitamin C may be used in doses of from 1mg to 5000mg per day,

CLAIMS

1. A pharmaceutical formulation comprising one or more EFAs selected from those shown in Fig. 1 together with one or more homocysteine-lowering agents, selected from Vitamin B12, folic acid, a compound related to folic acid with similar biological activity and vitamin B6, and a pharmaceutically acceptable excipient.
5
- 10 2. A nutritional formulation in the dosage form of a hard or soft gelatin capsule comprising one or more EFAs selected from those shown in Fig. 1 together with one or more homocysteine-lowering agents selected from Vitamin B12, folic acid, a compound related to folic acid with similar biological activity and vitamin B6.
15
- 20 3. A pharmaceutical or nutritional formulation comprising one or more EFAs selected from those shown in Fig. 1 together with one or more homocysteine-lowering agents selected from Vitamin B12, folic acid, a compound related to folic acid with similar biological activity and vitamin B6, the formulation comprising 200 μ g or more of the one or more homocysteine-lowering agents.
25
4. A formulation according to any preceding claim in which the EFA is eicosapentaenoic acid (EPA).
- 30 5. A formulation according to any of claims 1-3 in which the EFA is eicosapentaenoic acid (EPA) in the form of the ethyl ester or of the pure tri-EPA triglyceride.
6. A formulation according to any of claims 1-3 in which the EFA is arachidonic acid.


7. A formulation according to any of claims 1-3 in which the EFA is gammalinolenic acid or dihomogammalinolenic acid.
- 5 8. A formulation according to any of claims 1 to 3 in which the EFA is docosahexaenoic acid.
9. A formulation according to any preceding claim comprising two or more EFAs.
- 10 10. A formulation according to any preceding claim comprising at least 5% EFA, preferably more than 15% EFA, very preferably more than 30%, more than 50%, more than 90% or more than 95% EFA.
- 15 11. A formulation according to any preceding claim comprising vitamin B12, preferably in the form of hydroxocobalamin, as the only homocysteine-lowering agent.
- 20 12. A formulation according to any of claims 1 - 10 comprising folic acid or a related compound with similar biological activity as the only homocysteine-lowering agent.
- 25 13. A formulation according to any preceding claim in a form suitable for oral administration.
- 30 14. A formulation according to any preceding claim further comprising one or more antioxidants selected from natural, synthetic or semi-synthetic forms of vitamin E, coenzyme Q, alpha-lipoic acid and vitamin C.

15. A formulation according to any of claims 1 and 3 - 14 for use in therapy or prevention or for the manufacture of a medicament for use in therapy or prevention of one or more of the following conditions:

- 5 a. Any illness.
- 10 b. Any cardiovascular or cerebrovascular disorder, including any form of atherosclerosis of the coronary, cerebral or peripheral blood vessels, any form of heart disease, any form of cerebrovascular disease or stroke, any form of peripheral vascular disease and any form of thrombosis.
- 15 c. Any form of diabetes or pre-diabetes (syndrome X) and any of the macro- or microvascular complications of diabetes including cardiovascular disease, retinopathy, nephropathy or neuropathy.
- 20 d. Any form of psychiatric disorder including schizophrenia, schizotypal disorder and other schizopreniform disorders, bipolar disorder (mania, or manic depression), depression of any form, and panic or anxiety disorders, sleep disorders and social phobias.
- 25 e. Any form of neurological or neurodegenerative disorder including Alzheimer's disease and other forms of dementia, Parkinson's disease, multiple sclerosis, Huntington's disease and any form of chronic pain.
- 30 f. Any form of kidney disorder.
- g. Any form of inflammatory or immunological disorder of the gastrointestinal tract, the respiratory system, the skin and mucous membranes, or the joints or any other tissues.

- h. Any form of eye or hearing disorder including age-related macular degeneration, age-related deafness, or tinnitus.
- I. Any form of obesity, and particularly any method of treatment of obesity.
- 5
- j. Any form of cancer.

Fig. 1



1C866 U.S. PRO
09/615736
07/13/00